Close Menu

NEW YORK (360Dx) – Urine-based drug testing company Ameritox, which bills itself as the nation's leader in pain medication monitoring, is planning to cease operations this week, according to company officials.

The company has stopped accepting urine samples and its last day of operations will be Friday, May 4, according to George Athas, director of marketing and product management.

Some of the company's assets have been sold to Aegis Sciences, Athas said, but he was not familiar with the specifics of the transaction.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.